pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Bagsværd, JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
NovoThirteen patents
0 pharmaceutical patents indexed for NovoThirteen. 0 expire within 24 months.
NovoThirteen has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does NovoThirteen have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do NovoThirteen patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.